Navigation Links
Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
Date:1/7/2008

ogram aimed toward the development of longer acting Factor VIII therapies.

In accordance with generally accepted accounting principles, Baxter expects to record a special pre-tax charge of approximately $5 million for in- process research and development associated with the transaction in the fourth quarter of 2007. In addition, Baxter may make future development and sales milestone-related payments to Nektar.

Baxter Hemophilia Research and Development

Baxter is a global leader in hemophilia therapy, with innovations that span 40 years. Through its own scientific expertise and strategic partnerships, Baxter is applying novel technologies that will pioneer the next generation of hemophilia therapies. Baxter's goal is to greatly enhance treatment convenience through therapies that require fewer injections and offer non-intravenous dosing alternatives.

About Hemophilia and Hemophilia B

People with hemophilia do not produce adequate amounts of Factor VIII or Factor IX protein, which are necessary for blood to effectively clot. If untreated, patients with severe hemophilia have a greatly reduced life expectancy. According to the World Health Organization, more than 400,000 people in the world have hemophilia, corresponding to an incidence of 15 to 20 in every 100,000 males born worldwide. Hemophilia B is largely an inherited disorder in which the Factor IX protein needed to form blood clots is missing or reduced. In approximately 30 percent of cases, there is no family history of the disorder and the condition is the result of a spontaneous gene mutation. The first diagnosis of hemophilia B occurred in 1952.

About Baxter

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and bio
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
2. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
3. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014   Personal ... advanced cancer genome analysis and testing services, and ... and developing highly selective kinase inhibitors for genomically ... study of malignant mixed Mullerian tumors (MMMT), an ... system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:9/19/2014)... Food and Drug Administration approved a new type 2 diabetes ... of once-a-week injectable drugs that help manage blood sugar levels ... a new treatment option, which can be used alone or ... in the overall management of type 2 diabetes," Dr. Mary ... II, said in an agency news release. About ...
(Date:9/19/2014)... 2014 The Alliance for Bangladesh ... the National Fire Protection Association (NFPA), a recognized ... today in a Memorandum of Understanding signed by ... and other stakeholders with information, guidance and access ... health and safety of workers in ready-made garment ...
(Date:9/19/2014)... September 19, 2014 MetroMD, a leading anti-ageing ... “God Particle” of human health. This therapy has grown tremendously ... the therapy more effective, safe and dependable. It has far ... an opportunity to live a very healthy and active lifestyle ... of HGH therapy, a senior therapist at MetroMD said, “HGH ...
(Date:9/19/2014)... 2014 "I have difficulty putting in ... to stretching the skin around my eyes during the ... me to design a more convenient method of performing ... provides a quicker, easier, more sanitary method of putting ... this task manually, saves time and effort, and helps ...
(Date:9/19/2014)... (Sept. 19, 2014) - New research published today in ... Ebola cases could reach 6,800 in West Africa by ... are not enacted. , Arizona State University and ... the rate of rise in cases significantly increased in ... a mass quarantine was put in place, indicating that ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2
... part of its campaign to be the,leading provider of ... will be hosting "A Matter of Heart" Health Fair ... hear the latest expert,medical advice on heart disease prevention ... staff will also be performing,free cholesterol, carotid bruit, blood ...
... baby,s cord blood with M.A.Z.E. Cord Blood Laboratories in Purchase, NY. They ... to have it just in case. , ... Cresskill, NJ ... to bank their baby,s cord blood with M.A.Z.E. Cord Blood ...
... Seattle, December 8, 2008 Epileptologists are constantly searching for ... brain down to its most fundamental cellular and molecular detail ... to locate and treat the specific cells, neurons or network ... Another is to restore cognitive function after possible injury from ...
... Dr. Timothy McDonald, physician, attorney,and chief safety and risk ... Medical Center, will give the keynote address titled "The Legal ... Association,for Respiratory Care (AARC) International Respiratory Congress at the Anaheim,Convention ... One of the issues ...
... malignancies , , TUESDAY, Dec. 9 (HealthDay News) -- An ... bone marrow cancers called myeloproliferative disorders (MPDs), according to ... cells. , The findings were to be presented Tuesday ... Hematology, in San Francisco. , The researchers, from Oregon ...
... more commonly known as ,lazy eye, could be drastically ... Nottingham. , Amblyopia is thought to affect up to 2.5 ... cent of all children,s eye appointments in the UK. Occlusion ... ,train, the affected eye is the main treatment for ...
Cached Medicine News:Health News:Estero Urgent Care to Hold 'A Matter Of Heart' Health Fair, a Free Event Focusing on Heart Disease Prevention to be Held on December 21st at Estero Community Park 2Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 2Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 3Health News:Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy 4Health News:Researchers report on convergence of technology 2Health News:'A Principled Approach to Medical Mistakes' To Be Addressed at 54th Annual International Congress for Respiratory Therapists 2Health News:'A Principled Approach to Medical Mistakes' To Be Addressed at 54th Annual International Congress for Respiratory Therapists 3Health News:Lazy eye treatment times could be drastically reduced, new research shows 2
Inquire...
... are accurate to 1 mm. In vivo results ... patients encapsulation scar tissue. Encapsulation scar tissue can ... therefore actual projection may vary from patient to ... surgeon with a scalpel or surgical scissors. All ...
... IQmarkTM Diagnostic Workstation Software offers a ... that digitally stores many different diagnostic ... Microsofts open-architecture products in mind, our ... integration (using ActiveX controls), networking, central ...
... engineered to set a new standard for ... enter the patient demographics, select auto report ... based system uses the latest in software ... of the IQmark Holter algorithm. Simple, intuitive ...
Medicine Products: